BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment

Summary We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored BRAF V600E mutation. Standard chemotherapy with doxorubicin and ifosfamide failed to slow the disease progression. Subsequent administration of vemurafenib (960 mg twice a day) resulted in complete tumo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Investigational new drugs 2015-10, Vol.33 (5), p.1136-1143
Hauptverfasser:	Protsenko, Svetlana A., Semionova, Anna I., Komarov, Yuri I., Aleksakhina, Svetlana N., Ivantsov, Alexandr O., Iyevleva, Aglaya G., Imyanitov, Evgeny N.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Cancer therapies Chemotherapy Clinical outcomes Drug resistance Drugs Humans Indoles - adverse effects Indoles - therapeutic use Inhibitor drugs Kinases Male Medicine Medicine & Public Health Melanoma Metastasis Middle Aged Mutation Oncology Patients Pharmacology/Toxicology Proto-Oncogene Proteins B-raf - genetics Sarcoma Sarcoma, Clear Cell - drug therapy Short Report Skin Neoplasms - drug therapy Studies Sulfonamides - adverse effects Sulfonamides - therapeutic use Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary We report a patient with a metastatic relapse of clear cell sarcoma, whose tumor harbored BRAF V600E mutation. Standard chemotherapy with doxorubicin and ifosfamide failed to slow the disease progression. Subsequent administration of vemurafenib (960 mg twice a day) resulted in complete tumor response after 8 weeks of treatment. Literature data on the use of vemurafenib and dabrafenib in non-melanoma BRAF -mutated tumors are reviewed.
ISSN:	0167-6997 1573-0646
DOI:	10.1007/s10637-015-0280-0